“Expert Clinical Framework Report: Management of Adverse Events Related to Novel Therapies for Relapsed Refractory Multiple Myeloma (RRMM)”. 2022. Canadian Hematology Today 1 (S11). https://doi.org/10.58931/cht.2022.1S1130.